Autoimmune Brain Panel™ of tests

These markers are human serum Immunoglobulin G (IgG) levels by Enzyme-Linked ImmunoSorbent Assay (ELISA) directed against: Dopamine D1 Receptor (DRD1), Dopamine D2L Receptor (DRD2L), Lysoganglioside-GM1 (LYSO-GM1) and Tubulin (TUB). ELISA results are determined by measuring the colorimetric intensity at a specific wavelength which is directly proportional to the amount of antibody in the sample. The fifth assay of this panel measures the specific activity of calcium/calmodulin-dependent protein kinase II (CaM KII) induced by the patient serum in cultured human neuronal cell lines compared to controls. This panel measures the level of these antibodies, and the ability of the patient’s sera to stimulate CaM KII at a single point in time.

If one or more of these five assay values is elevated, it may indicate a clinically significant autoimmune neurological condition. This is a condition in which the patient’s autoantibodies cross-react and are directed against selected neuronal targets in the brain which are involved in neuropsychiatric and/or motor functions.

For further information on the panel and these markers, please see https://www.moleculera.com/about-autoimmune-brain-panel/.
To order the test please contact AONM on +44 (0)3331 210 305. Download the order form.